Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver Disease at High Cardiovascular Risk.
1/5 보강
[BACKGROUND & AIMS] Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and high cardiovascular risk often have advanced liver fibrosis, but data on associations and outcome
- p-value P < .001
- 95% CI 1.46-2.29
- 추적기간 4.5 years
APA
Zhou XD, Chen QF, et al. (2026). Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver Disease at High Cardiovascular Risk.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. https://doi.org/10.1016/j.cgh.2026.01.038
MLA
Zhou XD, et al.. "Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver Disease at High Cardiovascular Risk.." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026.
PMID
41655804 ↗
Abstract 한글 요약
[BACKGROUND & AIMS] Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and high cardiovascular risk often have advanced liver fibrosis, but data on associations and outcomes are limited. The aim of this study was to evaluate the relationships between cardiovascular risk categories and liver fibrosis severity, liver fibrosis progression, and liver-related events (LREs) in MASLD.
[METHODS] Patients with MASLD from the VCTE-Prognosis cohort were stratified into low, intermediate, and high cardiovascular risk categories using the Framingham Risk Score (FRS), Primary Care Equivalents (PCE), or Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) scores. Outcomes included the prevalence of advanced fibrosis (liver stiffness ≥10 kPa), liver stiffness progression (≥20% increase and Baveno category upshift), and LRE (hepatocellular carcinoma, hepatic decompensation, liver transplantation, or liver-related mortality). Associations were assessed using multivariable logistic regression and Fine-Gray competing-risks models.
[RESULTS] Among 9312 patients with MASLD (mean age, 54.4 ± 11.0 years; 56.8% male; 87.4% Asian), advanced fibrosis prevalence increased with cardiovascular risk: adjusted odds ratios (ORs) were 2.72 (95% confidence interval [CI], 2.25-3.28; P < .001) for FRS, 1.83 (95% CI, 1.46-2.29; P < .001) for PCE, and 2.93 (95% CI, 2.33-3.69; P < .001) for PREVENT. Over a median follow-up of 4.5 years, liver stiffness progression occurred in 5.0% of patients, more frequently in high-risk groups (adjusted subdistribution hazard ratio [SHR], 1.56; 95% CI, 1.14-2.15; P = .006 for PCE and adjusted SHR, 1.85; 95% CI, 1.33-2.56; P < .001 for PREVENT). LREs occurred in 1.4% of patients, with higher incidence in high-risk groups (adjusted SHR, 2.12; 95% CI, 1.19-3.77; P = .010 for FRS; adjusted SHR, 2.01; 95% CI, 1.08-3.74; P = .027 for PCE; and adjusted SHR, 2.80; 95% CI, 1.40-5.61; P = .004 for PREVENT).
[CONCLUSIONS] Higher cardiovascular risk is associated with greater prevalence of advanced liver fibrosis, liver stiffness progression, and LRE incidence in MASLD.
[METHODS] Patients with MASLD from the VCTE-Prognosis cohort were stratified into low, intermediate, and high cardiovascular risk categories using the Framingham Risk Score (FRS), Primary Care Equivalents (PCE), or Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) scores. Outcomes included the prevalence of advanced fibrosis (liver stiffness ≥10 kPa), liver stiffness progression (≥20% increase and Baveno category upshift), and LRE (hepatocellular carcinoma, hepatic decompensation, liver transplantation, or liver-related mortality). Associations were assessed using multivariable logistic regression and Fine-Gray competing-risks models.
[RESULTS] Among 9312 patients with MASLD (mean age, 54.4 ± 11.0 years; 56.8% male; 87.4% Asian), advanced fibrosis prevalence increased with cardiovascular risk: adjusted odds ratios (ORs) were 2.72 (95% confidence interval [CI], 2.25-3.28; P < .001) for FRS, 1.83 (95% CI, 1.46-2.29; P < .001) for PCE, and 2.93 (95% CI, 2.33-3.69; P < .001) for PREVENT. Over a median follow-up of 4.5 years, liver stiffness progression occurred in 5.0% of patients, more frequently in high-risk groups (adjusted subdistribution hazard ratio [SHR], 1.56; 95% CI, 1.14-2.15; P = .006 for PCE and adjusted SHR, 1.85; 95% CI, 1.33-2.56; P < .001 for PREVENT). LREs occurred in 1.4% of patients, with higher incidence in high-risk groups (adjusted SHR, 2.12; 95% CI, 1.19-3.77; P = .010 for FRS; adjusted SHR, 2.01; 95% CI, 1.08-3.74; P = .027 for PCE; and adjusted SHR, 2.80; 95% CI, 1.40-5.61; P = .004 for PREVENT).
[CONCLUSIONS] Higher cardiovascular risk is associated with greater prevalence of advanced liver fibrosis, liver stiffness progression, and LRE incidence in MASLD.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- CAR-T cells targeting activated hepatic stellate cells ameliorate liver fibrosis in mouse models.
- Insulin Growth Factor Binding Protein-6 and the Liver.
- T1rho MRI as a quantitative biomarker of radiation-induced liver disease in normal and fibrotic rat models.
- Correction: Identification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis.
- GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes.
- Senescent hepatic stellate cells drive inflammation and disease progression in MASH (Review).